Alere (ALR) : Mondays money flow data in Alere (ALR) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $17.04 million, whereas, $5.98 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 2.85, in favor of the bulls. The total money flow into the stock was $11.06 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $11.29 million. The total value of block trades done on upticks was $11.29 million.The up/down ratio in the block trades was a healthy 7783.71 in favor of the bulls, suggesting strong buying in the stock by large traders. Alere (ALR) fell $0.36 and traded at $43.26, down -0.83% for the day, over previous days close. On a weekly basis, the shares are 8.75% over the previous weeks close.
Alere Inc. has dropped 13.2% during the last 3-month period . Year-to-Date the stock performance stands at 10.67%. Shares of Alere Inc. rose by 8.29% in the last five trading days and 2% for the last 4 weeks. In a related news, The Securities and Exchange Commission has divulged that Flakne Carla, officer (VP, Chief Accounting Officer) of Alere Inc., had unloaded 10,000 shares at an average price of $42.44 in a transaction dated on January 16, 2015. The total value of the transaction was worth $424,400.
Alere (NYSE:ALR): On Mondays trading session , Opening price of the stock was $43.9 with an intraday high of $44.079. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $42.885. However, the stock managed to close at $43.26, a loss of 0.83% for the day. On the previous day, the stock had closed at $43.62. The total traded volume of the day was 1,054,938 shares.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).